EN Hikma Annual report 2020 Better health. Within reach. Every day. We create high-quality medicines and make them accessible to people who need them. Global experts with a local presence, we think creatively and act practically. We develop innovative solutions that transform people’s lives, for a healthier world wherever we are. PDF Full Annual Report Strategic report Executive Chairman and CEO's statements Business and financial review Corporate governance Financial statements Notice of Annual General Meeting Messages from the Board The strategy we set out when Siggi joined Hikma in 2018 is delivering results. I would like to thank all of our employees, as well as our customers, suppliers, shareholders and other stakeholders as we look forward to continued success in 2021." Said Darwazah Executive Chairman We faced a year of challenges and opportunities in 2020. I am enormously proud of how adaptive and resilient our employees were in the face of a global pandemic and am grateful for their unwavering commitment to maintaining the supply of vital medicines for patients across our markets." Sigurdur Olafsson Chief Executive Officer Performance Our latest results See all financial information Revenue ($m) $2,341m Operating profit ($m) $579m 1 2 3 4 Notes Five reasons to invest in Hikma We have a track record of creating value for our shareholders. By focusing on our strategic priorities and leveraging our strengths, we can build upon our success. Previous 1 Unique and diversified business model Our business is uniquely positioned, with three main business segments. We have a broad and diversified product portfolio and a growing pipeline of new medicines, that are sold in the retail and hospital markets. 2 Strong market position We are the third largest generic injectable manufacturer and a top ten generic company in the US. In MENA, we are one of the largest pharmaceutical companies with very strong brand awareness. Next 1 of 5 Our business model Our business model enables us to respond to the many opportunities and challenges we face. Find out more Our strategy By focusing on our strategy, we will deliver sustainable growth over the long-term. Find out more Our operations Injectables Our Injectables business develops and manufactures generic injectable products. Our products are sold across our markets and are primarily used in hospitals. Core revenue ($m) 42% of Group revenue (2019: 40%) Generics Our Generics business develops and manufactures oral and other non-injectable generic products. Our products are sold in the US retail market. Revenue ($m) 32% of Group revenue (2019: 33%) Branded Our Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in MENA. Our products are sold in the retail and hospital markets. Revenue ($m) 26% of Group revenue (2019: 26%) Downloads and resources PDF Full Annual Report PDF Strategic report PDF Executive Chairman and CEO’s statements PDF Business and financial review PDF Corporate governance PDF Financial statements PDF Notice of Annual General Meeting Investors 2020 annual report Back to top Useful links About Products Investors News Careers Contact Worldwide Leadership Stay in touch Subscribe to our newsletter Follow us instagram Created with Sketch. © Hikma Pharmaceuticals PLC 2021 Terms of use Cookie policy Disclaimer Privacy policy Community guidelines Our website uses cookies to improve your experience. Some of the cookies we use are essential for parts of our website to operate. By using our website without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.